HHS Public Access Author manuscript Am J Kidney Dis. Author manuscript; available in PMC 2017 July 05.
|
|
- Geraldine Stewart
- 5 years ago
- Views:
Transcription
1 HHS Public Access Author manuscript Published in final edited form as: Am J Kidney Dis March ; 69(3): doi: /j.ajkd Performance of the Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in a longitudinal study of Autosomal Dominant Polycystic Kidney Disease Chengli Shen, Ph.D. *, Douglas Landsittel, Ph.D. *, María V. Irazabal, M.D., Alan S.L. Yu, M.B., B.Chir., Arlene B. Chapman, M.D. #, Michal Mrug, M.D. &, Jared J. Grantham, M.D., Kyongtae T. Bae, M.D., Ph.D. *, William M. Bennett, M.D., Michael F. Flessner, M.D., Ph.D., and Vicente E. Torres, M.D., Ph.D. on behalf of the CRISP Investigators/Study Group * University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Mayo Clinic College of Medicine, Rochester, Minnesota Kansas University Medical Center, Kansas City, Kansas # University of Chicago, Chicago, Illinois & University of Alabama, Birmingham, Alabama Legacy Good Samaritan Hospital, Portland, Oregon National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland Glomerular filtration rate (GFR) can only be measured indirectly 1. The gold standard is the renal clearance of inulin. Because it is cumbersome, alternative methods such as the renal clearance of iothalamate and plasma clearance of iohexol were developed. Other methods estimate GFR using equations based on endogenous filtration markers such as creatinine and cystatin C 2. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is recommended for GFR estimation. Whether egfr is sufficiently accurate in longitudinal studies of Autosomal Dominant Polycystic Kidney Disease (PKD, ADPKD) is controversial 3. A comparison with plasma iohexol clearance at two time points over one year questioned its reliability 4. Because of the small number of patients and the inability to estimate slopes, long-term adequately powered studies were recommended. Here we compare the performance of measured (mgfr) and egfr in the Consortium for Renal Imaging Studies of PKD (CRISP) 5 7, a prospective study of 241 patients, yearold, with an initial creatinine clearance >70 ml/min, and measurements of height adjusted total kidney volume (HtTKV), mgfr by the iothalamate clearance 5 and serum creatinine Corresponding author: Vicente E. Torres, M.D. Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN phone fax, torres.vicente@mayo.edu. CONTRIBUTIONS Research idea and study design: CS, DL, MVI, VET; data acquisition: ASLY, ABC, MM, JJG, VET; image analysis: KTB; statistical analysis: CS, DL; data analysis: CS, DL, MVI, WMB, MFF, VET. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. VET takes responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
2 Shen et al. Page 2 yearly during four years and biennially thereafter 8. To adjust for calibration bias, serum samples were exchanged between the four study sites and the Cleveland Clinic Laboratory and calibration equations were derived for each site. In the earlier CRISP publication by Rule et al analyses were conducted with and without calibration 9. As reported in this publication, there was good agreement between the egfr slopes with and without calibration and the predictor associations did not change with the calibrations. Bias was defined as mgfr minus egfr; precision as the standard deviation of bias; accuracy as the percentage of egfr values within 10% (P10) or 30% (P30) of mgfr values. Linear mixed coefficient models (random intercept and slope), accounting for within subject correlation and assuming random variation of annual GFR changes between subjects, were used to calculate egfr and mgfr slopes. Pearson correlation coefficients between GFR values and slopes were calculated. Relationships of HtTKV and change in HtTKV (adjusted for age, gender and race) with mgfr and egfr were analyzed by linear mixed models. Statistical significance was defined as two sided p<0.05. Baseline characteristics of the CRISP cohort are shown in Table 1. At all visits, mean mgfr was higher than egfr (Figure 1A and Supplemental Table 1). At baseline, mean bias and precision of egfr were 5.2 and 21.9 ml/min/1.73 m 2 (Table 1). The bias was greater at high levels of egfr (Supplemental Figure 1). The annual change of bias during the duration of the study was 0.21 ml/min/1.73 m 2 (p=0.126). P10 and P30 values at baseline were 33.5 and 83.5% (Table 1). egfr and mgfr were significantly correlated at all time-points, increasingly from baseline (r=0.62) to year 12 (r=0.92) (Supplemental Figure 2). During 12 years of follow-up mgfr and egfr decreased from 97.8±24.7 and 92.6±22.7 to 65.2±38.6 and 58.6±32.0 ( 32.6±33.9 and 32.9±30.8 ml/min/1.73 m 2, respectively; Figure 1A and Supplemental Table 1). Mean egfr and mgfr slopes were similar ( 2.6 and 2.5 ml/min/1.73m 2 /year, P = 0.12). Mean bias and precision of egfr slopes were 0.1 and 1.1 ml/min/1.73m2/year, respectively. P10 and P30 were 22.0% and 70.3%. egfr and mgfr slopes were significantly correlated (r = 0.77, P<0.001; Figure 1B). Multivariable analyses adjusting for age, gender and race showed that HtTKV at baseline and change in HtTKV were significantly associated with the rates of mgfr decline at 8 and 12 years and of egfr decline at 4, 8 and 12 years of follow-up (Supplemental Table 2). The strengths of the associations, reflected by the beta coefficients, were modestly higher for mgfr than for egfr, but this advantage was offset by larger standard errors and did not impact the statistical significance. Four studies have measured the bias, precision and accuracy of egfr compared to mgfr in ADPKD 4,8,10 (Supplemental Table 3). In general the bias of egfr is greater and the accuracy less when the mgfr values are high. The mean GFR of the patients in our study was higher than that of the patients in the other three studies, accounting for the larger bias and lower precision of egfr in our study. Indeed, we found that bias was high and precision low when mgfr was 70, whereas the reverse was true when mgfr was <70 ml/min/1.73 m 2 (Supplemental Table 3).
3 Shen et al. Page 3 Four studies including the present 4,8,9 inform on the performance of egfr as compared to mgfr to detect changes in renal function in longitudinal studies. Rule et al found that baseline predictors of disease progression in CRISP correlated slightly better with mgfr compared to egfr slopes 9. Ruggenenti et al reported a greater decline over one year using mgfr compared to egfr 4. Spithoven et al showed a strong correlation between egfr and mgfr and similar rates of GFR decline over three years with both methods 8. By comparison to the previous analysis of CRISP with only three years a follow-up and no significant change in mean egfr or mgfr 9, the current analysis includes 12 years of follow-up during which mean egfr and mgfr decreased substantially. This updated analysis shows that both methods detect similar and strongly correlated changes in GFR and are equally capable to detect the associations of baseline HtTKV and of change in HtTKV with the rate of decline in GFR. Supplementary Material Acknowledgments References Refer to Web version on PubMed Central for supplementary material. SUPPORT AND FINANCIAL DISCLOSURE The CRISP study is supported by cooperative agreements from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (DK056943, DK056956, DK056957, DK056961). This study was also supported in part by the NIDDK through P30 grants to the Kansas PKD Research and Translation Core Center (DK106912) and the Mayo Translational PKD Center (DK090728), by the National Center for Research Resources General Clinical Research Centers at each institution (RR000039, Emory University; RR00585, Mayo College of Medicine; RR23940, Kansas University Medical Center; RR000032, University of Alabama at Birmingham), and the National Center for Advancing Translational Sciences Clinical and Translational Science Awards at each institution (RR and TR000454, Emory; RR and TR000135, Mayo College of Medicine; RR and TR000001, Kansas University Medical Center; RR025777, TR and TR001417, University of Alabama at Birmingham; RR and TR000005, University of Pittsburgh School of Medicine). The investigators are indebted to the study coordinators in CRISP. 1. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014; 63: DOI: /j.ajkd [PubMed: ] 2. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156: W-270, W-271, W-272, W-273, W-274, W-275, W-276, W-277, W-278. DOI: / [PubMed: ] 3. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88: [PubMed: ] 4. Ruggenenti P, Gaspari F, Cannata A, et al. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One. 2012; 7:e32533.doi: /journal.pone [PubMed: ] 5. Chapman A, Guay-Woodford L, JJG, et al. Renal structure in early autosomal dominant polycystic kidney disease (ADPKD); the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int. 2003; 64: [PubMed: ] 6. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006; 354: [PubMed: ]
4 Shen et al. Page 4 7. Chapman AB, Bost JE, Torres VE, et al. Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2012; 7: CJN [pii]. DOI: /CJN [PubMed: ] 8. Spithoven EM, Meijer E, Boertien WE, et al. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. AM J Kidney Dis. 2013; 62: DOI: /j.ajkd [PubMed: ] 9. Rule AD, Torres VE, Chapman AB, et al. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006; 17: [PubMed: ] 10. Orskov B, Borresen ML, Feldt-Rasmussen B, et al. Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2010; 31: DOI: / [PubMed: ]
5 Shen et al. Page 5 Figure 1. A. Dynamic changes of egfr and mgfr over time. B. Correlations of egfr slopes and mgfr slopes; the regression line (solid black) and line of identity (black dash) are shown; intercept (CI 1.00, 0.844); slope (CI 0.584, 0.634).
6 Shen et al. Page 6 Table 1 Patient Characteristics and Measures of Performance of the CKD-EPI Equation at Baseline Using mgfr as Reference Variable N (%) Mean SD Gender Race Male 96 (40) Female 145 (60) White 209 (86.7) Nonwhite 32 (13.3) Age (years) Height (cm) BSA (m 2 ) BMI Diastolic BP (mmhg) Systolic BP (mmhg) TKV (ml) HtTKV (ml/m) Serum creatinine (mg/dl) Urine albumin (mg/24h) * 12.0, 51.0 * mgfr (ml/min/1.73 m 2 ) egfr (ml/min/1.73 m 2 ) Bias (ml/min/1.73 m2) Precision (ml/min/1.73 m2) P30 (%) P10 (%) Body Mass Index (BMI); Height Adjusted TKV (HtTKV); Total Kidney Volume(TKV); Body Surface Area (BSA) * Median and interquartile range Bias= mgfr minus egfr; Precision=SD of bias. P30 and P10= percentage of egfr estimates within 30% or 10% of mgfr
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort
McKenzie et al. BMC Nephrology (2018) 19:378 https://doi.org/10.1186/s12882-018-1182-0 RESEARCH ARTICLE Open Access Relationship between caffeine intake and autosomal dominant polycystic kidney disease
More informationTo treat patients with early chronic kidney disease
Comparison of Methods for Determining Renal Function Decline in Early Autosomal Dominant Polycystic Kidney Disease: The Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease Cohort Andrew
More informationclinical investigation see commentary on page 14
clinical investigation http://www.kidney-international.org 21 International Society of Nephrology see commentary on page 14 A comparison of ultrasound and magnetic resonance imaging shows that kidney length
More informationShuma Hirashio 1,2, Shigehiro Doi 1 and Takao Masaki 1*
Hirashio et al. Renal Replacement Therapy (2018) 4:24 https://doi.org/10.1186/s41100-018-0164-9 CASE REPORT Open Access Magnetic resonance imaging is effective for evaluating the therapeutic effect of
More informationSUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist. Hirslanden, 22 March 2018 Stefan Russmann
SUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist Hirslanden, 22 March 2018 Stefan Russmann 4 th of July 2004 Database development with outcomes and safety
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2018 February 01.
Dietary salt restriction is beneficial to the management of Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, MD PhD, Kaleab Z. Abebe, PhD, Robert W. Schrier, MD, Ronald D. Perrone, MD, Arlene
More informationUniversity of Groningen. Autosomal dominant polycystic kidney disease Spithoven, Edwin
University of Groningen Autosomal dominant polycystic kidney disease Spithoven, Edwin IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationThese authors contributed equally to this work. These authors are joint senior authors on this work. *
RESEARCH ARTICLE Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease Laia Sans 1,2,3, Aleksandar Radosevic 4, Claudia
More informationADPKD, what have the last 10 years taught us? Arlene B. Chapman MD Professor of Medicine Director, Section of Nephrology University of Chicago
2016 ADPKD, what have the last 10 years taught us? Arlene B. Chapman MD Professor of Medicine Director, Section of Nephrology University of Chicago 2016 Can we TRUMP the cysts? Disclosures Consultant for
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationVolume Progression in Polycystic Kidney Disease
The new england journal of medicine original article Volume Progression in Polycystic Kidney Disease Jared J. Grantham, M.D., Vicente E. Torres, M.D., Arlene B. Chapman, M.D., Lisa M. Guay-Woodford, M.D.,
More informationTolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial Niek F. Casteleijn, University of Groningen Jaime D. Blais,
More informationSegmentation of Individual Renal Cysts from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease
Article Segmentation of Individual Renal Cysts from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease Kyungsoo Bae,* Bumwoo Park,* Hongliang Sun,* Jinhong Wang,* Cheng Tao,* Arlene
More informationMeasurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE
Measurement and Estimation of renal function Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE 1 2 How to estimate GFR? How to measure GFR? How to estimate GFR? How to measure GFR?
More informationTotal Kidney Volume (TKV) in Autosomal Dominant Polycystic Kidney Disease as model for biomarker qualification
Total Kidney Volume (TKV) in Autosomal Dominant Polycystic Kidney Disease as model for biomarker qualification Roslyn Simms NIHR Clinical Lecturer in Nephrology NIHR Clinical Trials Fellow Monday 23 rd
More informationΕκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης
Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης Ιατρική Σχολή ΑΠΘ Νοσοκομείο ΑΧΕΠA Θεσσαλομίκη Kidney in body homeostasis Excretory function Uremic toxins removal Vascular volume maintainance Fluid-electrolyte
More informationMeasurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE
Measurement and Estimation of renal function Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE 1 2 How to estimate GFR? How to measure GFR? How to estimate GFR? How to measure GFR?
More informationAge- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases
https://doi.org/10.1007/s10157-018-1617-8 ORIGINAL ARTICLE Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases Eiji Higashihara 1 Kouji Yamamoto 5
More informationLaura Girardat-Rotar 1, Julia Braun 1, Milo A. Puhan 1, Alison G. Abraham 1,2 and Andreas L. Serra 1,3*
Girardat-Rotar et al. BMC Nephrology (2017) 18:241 DOI 10.1186/s12882-017-0654-y RESEARCH ARTICLE Open Access Temporal and geographical external validation study and extension of the Mayo Clinic prediction
More informationA Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease
A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease Dawei Xie,* Marshall M. Joffe,* Steven M. Brunelli,* Gerald Beck, Glenn M. Chertow,
More informationABSTRACT. n engl j med 371;24 nejm.org december 11,
The new england journal of medicine established in 1812 december 11, 2014 vol. 371 no. 24 Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease Robert W. Schrier, M.D., Kaleab Z. Abebe,
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationIs the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?
Diabetes Care Publish Ahead of Print, published online October 3, 2008 The MCQ equation in DM2 patients Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration
More informationNephrology Grand Rounds. Vasishta Tatapudi, MD January 24 th, 2013
Nephrology Grand Rounds Vasishta Tatapudi, MD January 24 th, 2013 Case Summary Chief complaint: A twenty-six year old African American female veteran presented to ER with left flank pain for two days.
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationValidation of El-Minia Equation for Estimation of Glomerular Filtration Rate in Different Stages of Chronic Kidney Disease
Kidney Diseases Validation of El-Minia Equation for Estimation of Glomerular Filtration Rate in Different Stages of Chronic Kidney Disease Osama El Minshawy, 1 Eman El-Bassuoni 2 Original Paper 1 Department
More informationEstimates of glomerular filtration rate (GFR) from serum
Annals of Internal Medicine Review Estimating Equations for Glomerular Filtration Rate in the Era of Creatinine Standardization A Systematic Review Amy Earley, BS; Dana Miskulin, MD, MS; Edmund J. Lamb,
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationPage 1. Disclosures. Main Points of My Talk. Enlightened Views of Serum Creatinine, egfr, Measured GFR, and the Concept of Clearance
1 Enlightened Views of Serum Creatinine, egfr, Measured GFR, and the Concept of Clearance John Toffaletti, PhD Director of Blood Gas and Clinical Pediatric Laboratories Professor of Pathology Duke University
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationAssessing Renal Function: What you Didn t Know You Didn t Know
Assessing Renal Function: What you Didn t Know You Didn t Know Presented By Tom Wadsworth PharmD, BCPS Associate Clinical Professor UAA/ISU Doctor of Pharmacy Program Idaho State University College of
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationeditorial Steven J. Rosansky 1 and Richard J. Glassock 2 1 Dorn Research Institute, WJBD
http://www.kidney-international.org 2014 International Society of Nephrology editorial Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Kidney International
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationDominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging
158 Klinische Kurzstandards Recommendations for Diagnostic and Prognostic Evaluation of Autosomal The Swiss Society of Radiology (SGR- SSR) and the Swiss Society of Nephrology Working Group of Inherited
More informationPredictors of the progression of renal disease in the Modification of Diet in Renal Disease Study
Kidney International, Vol. 51 (/997), pp. 198 19/9 Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study MODIFICATION OF DIET IN RENAL DISEASE STUDY GROUP, prepared
More informationCharacteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests
Renal Tests Holly Kramer MD MPH Associate Professor of Public Health Sciences and Medicine Division of Nephrology and Hypertension Loyola University of Chicago Stritch School of Medicine Renal Tests 1.
More informationKDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4
KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAutosomal Dominant Polycystic Kidney Disease. Dr. Sameena Iqbal Nephrologist CIUSSS West Island
Autosomal Dominant Polycystic Kidney Disease Dr. Sameena Iqbal Nephrologist CIUSSS West Island Disclosure Honorarium for Consulting on the Reprise trial from Otsuka Mayo clinic preceptorship for PKD with
More informationCorrespondence should be addressed to Maisarah Jalalonmuhali;
Hindawi International Journal of Nephrology Volume 2017, Article ID 2901581, 7 pages https://doi.org/10.1155/2017/2901581 Research Article Comparative Performance of Creatinine-Based Estimated Glomerular
More informationCloseout of the HALT Polycystic Kidney Disease Treatment Network Trials
Closeout of the HALT Polycystic Kidney Disease Treatment Network Trials Society for Clinical Trials Philadelphia, PA Monday, May 19, 2014 Charity G. Moore, PhD Susan Spillane, RN, CCRP Marie Hogan, MD,
More informationThis is the author s version of a work that was accepted for publication after peer review. This is known as the post-print.
This is the author s version of a work that was accepted for publication after peer review. This is known as the post-print. Citation for author s accepted version Maple-Brown, Louise Janet, Hughes, Jaquelyne
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationGlomerular Filtration Rate Estimations and Measurements. Pierre Delanaye, MD, PhD University of Liège CHU Sart Tilman BELGIUM
Glomerular Filtration Rate Estimations and Measurements Pierre Delanaye, MD, PhD University of Liège CHU Sart Tilman BELGIUM Summary Estimating GFR (creatinine, egfr, cystatin C) Measuring GFR Summary
More informationIs tolvaptan a promising ally in the treatment strategy of autosomal dominant polycystic kidney disease?
PERSPECTIVE Port J Nephrol Hypert 2017; 31(4): 243-248 Advance Access publication 4 January 2018 Is tolvaptan a promising ally in the treatment strategy of autosomal dominant polycystic kidney disease?
More informationThe relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan
Environ Health Prev Med (2011) 16:191 195 DOI 10.1007/s12199-010-0183-9 SHORT COMMUNICATION The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Nobuyuki
More informationDepartment of Clinical Pathology, Faculty of Medicine Padjadjaran University-Dr. Hasan Sadikin General Hospital 2
Original Article Comparison of Estimated Glomerular Filtration Rate Mean Value of HARUS 15-30-60, HADI, and ASIAN Fomula Accuracy in Diabetes Mellitus Type 2 Sylvia Rachmayati, 1 Ida Parwati, 1 Abdul Hadi
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationPerformance of MDRD study and CKD-EPI equations for long-term follow-up of nondiabetic patients with chronic kidney disease
Nephrol Dial Transplant (2012) 27 (Supple 3): iii89 iii95 doi: 10.1093/ndt/gfr235 Advance Access publication 11 May 2011 Original Article Performance of MDRD study and CKD-EPI equations for long-term follow-up
More informationTitle:Impaired renal function and associated risk factors in newly diagnosed HIV-infected Adults in Gulu Hospital, Northern Uganda
Author's response to reviews Title:Impaired renal function and associated risk factors in newly diagnosed HIV-infected Adults in Gulu Hospital, Northern Uganda Authors: Pancras Odongo (odongopancras@gmail.com)
More informationPRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME
PRIMARY PHASE 2 ANALYSES FROM CARDINAL: A PHASE 2/3 STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME 217 American Society of Nephrology Meeting Geoffrey A. Block 1, Pablo E. Pergola 2, Lesley
More informationPrimary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationTolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article in Patients with Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, M.D., Ph.D., Arlene B. Chapman, M.D., Olivier Devuyst,
More informationEstimating GFR: From Physiology to Public Health. Outline of Presentation. Applications of GFR Estimations
stimating FR: From Physiology to Public Health Tufts: Andy Levey, Lesley (Stevens) Inker, Chris Schmid, Lucy Zhang, Hocine Tighiouart, Aghogho Okparavero, Cassandra Becker, Li Fan Hopkins: Josef Coresh,
More informationCase report: a thiazide diuretic to treat polyuria induced by tolvaptan
Kramers et al. BMC Nephrology (2018) 19:157 https://doi.org/10.1186/s12882-018-0957-7 CASE REPORT Open Access Case report: a thiazide diuretic to treat polyuria induced by tolvaptan Bart J. Kramers *,
More information2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives
Evaluation of egfr and mgfr in CKD Use of CKD staging with case scenario Assessment of kidney function in CKD in adults Learning Objectives 台大雲林分院楊淑珍藥師 2017/03/11 Chronic Kidney Disease (CKD) Based on
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationSupplementary Online Content
Supplementary Online Content Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic
More informationAssessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review
Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review AS Levey 1 and LA Inker 1 Acute and chronic kidney diseases affect pharmacokinetics and pharmacodynamics. There
More informationTolvaptan: Slowing Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tolvaptan: Slowing Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cardiovascular and Renal Drugs Advisory Committee August 5, 2013 Introduction Robert McQuade, PhD Executive Vice President
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationDoes increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?
NDT Advance Access published April 15, 2014 Nephrol Dial Transplant (2014) 0: 1 10 doi: 10.1093/ndt/gfu093 Original Article Does increased water intake prevent disease progression in autosomal dominant
More informationEquations to Estimate Creatinine Excretion Rate: The CKD Epidemiology Collaboration
Article Equations to Estimate Creatinine Excretion Rate: The CKD Epidemiology Collaboration Joachim H. Ix,* Christina L. Wassel, Lesley A. Stevens, Gerald J. Beck, Marc Froissart, Gerjan Navis,** Roger
More informationTolvaptan bei ADPKD: Kritische Beurteilung der Studien
Tolvaptan bei ADPKD: Kritische Beurteilung der Studien Johannes Mann & Stewart Lambie * KfH Nierenzentrum München Schwabing, Klinik für Nieren- & Hochdruckkrankheiten, Friedrich Alexander Univ. Erlangen-Nürnberg
More informationAutosomal-dominant polycystic kidney disease (AD-
Magnetic Resonance Imaging Evaluation of Hepatic Cysts in Early Autosomal-Dominant Polycystic Kidney Disease: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Cohort Kyongtae
More informationSupplementary Online Content
Supplementary Online Content Clark WF, Sontrop JM, Huang S-H et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: the CKD WIT Randomized
More informationCardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease
CJASN epress. Published on September 8, 2011 as doi: 10.2215/CJN.04610511 Article Cardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease Ronald D.
More informationMagnetic Resonance Imaging of Kidney and Cyst Volume in Children with ADPKD
Article Magnetic Resonance Imaging of Kidney and Cyst Volume in Children with ADPKD Melissa A. Cadnapaphornchai,* Amirali Masoumi, John D. Strain, Kim McFann, and Robert W. Schrier Summary Background and
More informationGrayscale ultrasound characteristics of autosomal dominant polycystic kidney disease severity an adult and pediatric cohort study
Original paper Cite as: Strzelczyk M, Podgórski M, Afshari S, Tkaczyk M, Pawlak-Bratkowska M, Grzelak P: Grayscale ultrasound characteristics of autosomal dominant polycystic kidney disease severity an
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAutosomal dominant polycystic kidney disease (ADPKD)
CJASN epress. Published on November 29, 2010 as doi: 10.2215/CJN.03780410 Magnetic Resonance Imaging of Kidney and Cyst Volume in Children with ADPKD Melissa A. Cadnapaphornchai,* Amirali Masoumi, John
More informationSummary of Recommendation Statements Kidney International Supplements (2013) 3, 5 14; doi: /kisup
http://www.kidney-international.org & 2013 DIGO Summary of Recommendation Statements idney International Supplements (2013) 3, 5 14; doi:10.1038/kisup.2012.77 Chapter 1: Definition and classification of
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAssessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation
Nephrol Dial Transplant (2002) 17: 1909 1913 Original Article Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new () prediction equation
More informationGFR and Drug Dosage Adaptation: Are We still in the Mist?
GFR and Drug Dosage Adaptation: Are We still in the Mist? Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM I have no conflict of interest to declare
More informationAcademic Insights for Biomarker Priorities and Candidate Pilot Project(s)
Academic Panel Session Academic Insights for Biomarker Priorities and Candidate Pilot Project(s) Moderators: Dr. Chirag Parikh (Yale) Dr. Kumar Sharma (UCSD) Panelists: Dr. Ronald Perrone (Tufts Medical
More informationA systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease
Woon et al. BMC Nephrology DOI 10.1186/s12882-015-0114-5 RESEARCH ARTICLE Open Access A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationKDIGO Controversies Conference on Autosomal Dominant Polycystic Kidney Disease (ADPKD)
KDIGO Controversies Conference on Autosomal Dominant Polycystic Kidney Disease (ADPKD) January 16 19, 2014 Edinburgh, United Kingdom Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More informationGlomerular filtration rate estimated by cystatin C among different clinical presentations
http://www.kidney-international.org & 2006 International Society of Nephrology Glomerular filtration rate estimated by cystatin C among different clinical presentations AD Rule 1,2, EJ Bergstralh 3, JM
More informationAngiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
The new england journal of medicine original article Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease Vicente E. Torres, M.D., Ph.D., Kaleab Z. Abebe, Ph.D., Arlene B. Chapman,
More informationEvaluation of the 1B Equation to Estimate Glomerular Filtration Rate in Pediatric Patients with Cancer
Brief Communication Clinical Chemistry Ann Lab Med 2018;38:261-265 https://doi.org/10.3343/alm.2018.38.3.261 ISSN 2234-3806 eissn 2234-3814 Evaluation of the Equation to Estimate Glomerular Filtration
More informationClinical Study Acute Kidney Injury in ADPKD Patients with Pneumonia
SAGE-Hindawi Access to Research International Nephrology Volume 2, Article ID 6794, 6 pages doi:.46/2/6794 Clinical Study Acute Kidney Injury in ADPKD Patients with Pneumonia Carlos Franco Palacios,, 2
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Age and Kidney Weight renal weight and thickening of the vascular intima Platt et al. Gerentology 1999;45:243-253
More information